Abstract

It is becoming increasingly common for pharmaceutical companies to submit pharmacoeconomic studies to national and local agencies when applying for inclusion of drugs on formularies or approved lists for reimbursement. In some cases pharmacoeconomic data are submitted to government agencies, such as the National Institute for Clinical Excellence (NICE) in the UK or the Pharmaceutical Benefits Advisory Committee in Australia. In other cases they are submitted, on request, to managed care groups or hospital formulary committees. Economic evaluations and/or studies of resource implications are also increasingly published on clinical practice guidelines web sites, by agencies such as the Scottish Intercollegiate Guidelines Network and the New Zealand Guidelines Group.